Abstract: The present embodiments of the invention disclose methods for implementing ZmARGOS9 gene in drought resistance and high yield of maize. ZmARGOS9 is overexpressed in maize in the present disclosure. The high expression of ZmARGOS9 gene improves the drought resistance and yield of maize. Accordingly, it enables enrichment of drought-resistant and high-yielding genes, contributing to the security of the seed industry.

Abstract: In various embodiments, methods, systems, software, and apparatuses for controlling devices of a facility are provided, e.g., based on user input and/or user preferences.

Abstract: A compound and a method of detecting CLN3 are provided. The compound includes a heavy isotope labeled CLN3 proteotypic peptide. The method includes i) selecting a CLN3 proteotypic peptide that exhibits linear behavior in the mass spectrometer; ii) generating a stable isotope labeled standard; iii) spiking known amounts of the stable isotope labeled standard into a sample to form a spiked sample; iv) determining retention times and establishing calibration curves using the spiked sample; and v) detecting unlabeled selected CLN3 proteins in the sample.

Abstract: Methods for generating patterned nanoparticle assemblies in thin films of supramolecular nanocomposites are provided that allow control over microdomain morphology, periodicity, and orientation by tuning the assembly kinetics and pathways of the system. Directed self-assembly (DSA) of block copolymers (BCPs) with nanoparticles formed on lithographically-patterned templates produce patterned supramolecular nanocomposite films and patterns of nanoparticles. DSA may be used to guide the formation of concentric rings with radii spanning approximately 150 nm to 1150 nm and ring widths spanning about 30 nm to 60 nm, for example. When plasmonic nanoparticles are used, ring nanodevice arrays can be fabricated in one step, and the completed devices produce high-quality orbital angular momentum (OAM).

Abstract: This disclosure relates to systems and methods for the observation and/or measurement of clot formation and/or contraction. The system includes reaction chambers arranged with an image capturing device to allow for quantification of clot side-view cross-sectional area over time to determine the kinetics of clot formation and/or contraction. By varying the cellular materials and test agents included in the reaction chambers, it is possible to determine the effect of any particular component may yield on clot contraction. The system provides low-cost set-up, robust software, and multi-sample capacity, thus is a sensitive and flexible system to be used as a “workhorse” tool in a regular laboratory setting for better understanding the molecular features of how platelets mediate clot contraction, with the potential for clinical usages and/or medium throughput laboratory testing and drug screens.

Abstract: Provided herein are methods, systems, apparatuses, and computer programs related to various devices in an enclosure, e.g., using identification capturing device such as in conjunction with a digital twin of the enclosure. The computer program may be utilized for commissioning, maintenance, sales, marketing, and/or customer service. The computer program may receive customer, and/or customer service, input. The computer program may facilitate use of customer and/or customer service, e.g., input for controlling the facility (e.g., various devices of the facility), input for structuring the facility, and/or input for placing assets such as devices of the facility.

Abstract: A compound and a method of detecting CLN3 are provided. The compound includes a heavy isotope labeled CLN3 proteotypic peptide. The method includes i) selecting a CLN3 proteotypic peptide that exhibits linear behavior in the mass spectrometer; ii) generating a stable isotope labeled standard; iii) spiking known amounts of the stable isotope labeled standard into a sample to form a spiked sample; iv) determining retention times and establishing calibration curves using the spiked sample; and v) detecting unlabeled selected CLN3 proteins in the sample.

Abstract: A charging station is provided for charging electronic devices that includes a housing comprising a back panel including one or more electrical connectors configured for placement against surface adjacent an outlet such that the one or more electrical connectors may be coupled to the outlet, one or more ports configured to receive charging cables from electronic devices, and a power distribution circuit within the housing for delivering electricity from the outlet coupled to the one or more electrical connectors and the one or more ports. A charging tray is mounted to the housing such that the charging tray is movable between a storage position and an active position, the charging tray including one or more slots for receiving an electronic device during charging.